GSK Commits $30 Billion to Bolster U.S. R&D and Manufacturing

GSK will invest $30 billion in the United States over the next five years to strengthen its local supply chain and enhance research and development (R&D) capabilities135.

The investment includes $1.2 billion earmarked for advanced production plants and the adoption of artificial intelligence and digital technologies, intended to create next-generation biopharma factories and laboratories1.

GSK plans to construct a new biologics production facility in Upper Merion, Pennsylvania, specifically for drugs addressing chronic obstructive pulmonary disease, asthma, and various cancers; work is expected to begin next year1.

Additional funds will be used to upgrade manufacturing sites in Pennsylvania, North Carolina, Maryland, and Montana1.

The initiative is anticipated to create hundreds of highly skilled jobs plus construction openings, but the precise number is not disclosed13.

This move follows an $800 million GSK investment in 2024, also focused on U.S. manufacturing expansion1.

GSK's commitment comes as several global pharmaceutical companies, such as Sanofi, Eli Lilly, Merck, AstraZeneca, and Roche, have also recently increased their U.S. investments in response to policy and market shifts1.

Sources:

1. https://www.biospace.com/business/gsk-commits-30b-to-boost-us-r-d-manufacturing-operations

3. https://businessfacilities.com/gsk-to-invest-30b-in-u-s-over-next-5-years

5. https://www.gsk.com/media/v3jb0woi/press-release-gsk-to-invest-30-billion-in-rd-and-manufacturing-in-the-united-states-over-next-5-years.pdf